Pearl Steinzor

People who regularly consumed yogurt had lower rates of colorectal cancer–positive Bifidobacterium.

Both drugs showed significant improvements, with higher response observed for bimekizumab, study finds.

Study results show most patients prefer more frequent colonoscopies, but specialist recommendations drive acceptance of extended intervals.

Aditya Bardia, MD, MPH, FASCO, medical oncologist, UCLA Health, provides new insights on the role of TROP2-directed antibody drug conjugates (ADCs) for patients with breast cancer.

High vaccine uptake shows promise for the prevention of respiratory syncytial virus (RSV) in infants.

The executive order calls for recommendations on how to expand access and reduce costs for in vitro fertilization (IVF) treatment.

A real-world study in Spain finds faster improvements with induction therapy but highlights long-term drug survival challenges.

Kim Newcomer, director of volunteers, Colorectal Cancer Alliance, shares findings from a survey on colorectal cancer care inequities, and how to address these challenges.

Racial and ethnic disparities were identified in immunotherapy receipt for Black patients with metastatic triple-negative breast cancer.

Higher calcium intake was associated with reduced colorectal cancer risk across tumor sites and calcium sources, according to one study.

Aditya Bardia, MD, MPH, FASCO, medical oncologist, UCLA Health, discusses findings from the TROPION-Breast01 study on datapotamab deruxtecan for patients with HR-positive/HER2-negative breast cancer.

Service utilization is the biggest factor behind spending variation, with prices, disease prevalence, and demographics playing smaller roles.

Roflumilast demonstrated effectiveness and safety in treating psoriasis, with added benefits for patients with comorbidities.

A follow-up of the ShortHER trial suggests tumor-infiltrating lymphocytes (TILs) can help identify patients who may benefit from shorter trastuzumab and chemotherapy regimens.

New data show states with abortion bans saw increased infant deaths, with the greatest impact on Black infants and congenital anomaly-related deaths.

Researchers have developed an evaluation protocol index to optimize postoperative recovery.

A consistent safety profile and sustained efficacy were observed in patients with moderate to severe plaque psoriasis.

Significant increases in breast cancer incidence were found among Hispanic, American Indian or Alaska Native, and Asian or Pacific Islander women.

Kim Newcomer, director of volunteers, Colorectal Cancer Alliance, discusses a study conducted with Takeda and the Harris Poll, focusing on the treatment experiences of patients with metastatic colorectal cancer.

All patients involved in the phase 1 trial of a personalized cancer vaccine for high-risk stage III/IV kidney cancer showed a successful anticancer immune response.

Breast cancer screening rates shifted after the 2009 US Preventive Services Task Force (USPSTF) guidelines, with disparities emerging across race, income, and lifestyle factors.

New research highlights the significant health care resource utilization burden of generalized pustular psoriasis (GPP), revealing higher hospitalizations and costs among patients experiencing flares.

New data showed that prior malignancy may influence survival outcomes in patients with metastatic colorectal cancer, highlighting the need for standardized treatment approaches.

Sarah Anderson, oncology strategy lead director, Novotech, discusses the significance of triple-negative breast cancer research in the Asia-Pacific region, and the importance of clinical trial diversity in this region.

Roche’s PATHWAY HER2 (4B5) test helps identify patients with HER2-ultralow breast cancer, who may be eligible for targeted therapy.

This week, Robert F. Kennedy Jr sat before the Senate for 2 separate hearings, to decide the fate of his confirmation as secretary of HHS.

Atezolizumab (Tecentriq) plus chemotherapy after surgery did not improve survival in high-risk triple-negative breast cancer, according to a global phase 3 trial.

Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.

The approval is based on findings from a phase 3 study which demonstrated the drug’s superiority over chemotherapy.

Sarah Anderson, oncology strategy lead director, Novotech, discusses the growing prominence of triple-negative breast cancer clinical trials in the Asia-Pacific region, and the significant investments being made with novel biomarkers.